m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG00297)
Name
7-Mercapto-heptanoic acid pyridin-3-ylamide
Synonyms
CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653
    Click to Show/Hide
Status
Investigative
Structure
Formula
C12H18N2OS
InChI
1S/C12H18N2OS/c15-12(7-3-1-2-4-9-16)14-11-6-5-8-13-10-11/h5-6,8,10,16H,1-4,7,9H2,(H,14,15)
InChIKey
SHPVLBRAGPXPLH-UHFFFAOYSA-N
PubChem CID
11345433
TTD Drug ID
D07FJU
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Histone deacetylase 2 (HDAC2)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Histone deacetylase 2 (HDAC2) is a therapeutic target for 7-Mercapto-heptanoic acid pyridin-3-ylamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 7-Mercapto-heptanoic acid pyridin-3-ylamide through regulating the expression of Histone deacetylase 2 (HDAC2). [1], [2]
References
Ref 1 The epitranscriptome m6A writer METTL3 promotes chemo- and radioresistance in pancreatic cancer cells. Int J Oncol. 2018 Feb;52(2):621-629. doi: 10.3892/ijo.2017.4219. Epub 2017 Dec 7.
Ref 2 Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates. J Med Chem. 2005 Feb 24;48(4):1019-32. doi: 10.1021/jm049207j.